AbbVie Ups Its IBD Game With Latest Crohn’s Data For Rinvoq

Last Of Three Phase III Readouts Also Positive

The leader in inflammatory bowel disease via Humira, AbbVie awaits a US FDA decision in June for Skyrizi in Crohn’s disease and plans to add a Crohn’s indication to Rinvoq’s ulcerative colitis approval.

Chain of arrows blocks — Crohn's disease is an important building block in AbbVie's Rinvoq strategy • Source: Shutterstock

AbbVie Inc. has a long leadership position in autoimmune diseases due to its top-selling TNF inhibitor Humira (adalimumab) and continues to build on its legacy in inflammatory bowel disease (IBD) via the newer blockbusters Skyrizi (risankizumab) and Rinvoq (upadacitinib). Approved in the US for ulcerative colitis in March, the company now has the data it needs to seek approvals for Rinvoq in Crohn’s disease while it awaits a US Food and Drug Administration decision in June that would make Crohn’s the first IBD indication for Skyrizi.

AbbVie reported top-line results on 11 May from the Phase III U-ENDURE clinical trial testing the JAK1 inhibitor Rinvoq versus...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Metsera’s Amylin Analog Stars In Obesity Phase I

09 Jun 2025

• By Joseph Haas

Intended as obesity monotherapy and for combination with the firm’s GLP-1 analog, MET-0233i showed best-in-class efficacy with placebo-like tolerability at low doses.

Merck & Co.’s Enlicitide Poised To Be First Oral PCSK9 Inhibitor To Market

09 Jun 2025

• By Jessica Merrill

The company announced positive data from two Phase III trials testing the cholesterol-lowering medicine.

Sanofi Cements RSV Dominance As Merck & Co. Rival Awaits FDA D-Day

09 Jun 2025

• By Kevin Grogan

The French company will start shipping its blockbuster shortly to meet expected strong demand in the 2025–26 RSV season.

Pipeline Watch: ASCO Dominates Phase III Readouts

09 Jun 2025

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Quick Listen: Scrip’s Five Must-Know Things

09 Jun 2025

• By Ian Haydock

In this week's episode: Sanofi’s Blueprint buy; AstraZeneca’s breast cancer resistance results at ASCO; BMS and BioNTech’s big bispecific deal; Kymera’s Dupixent in a pill; and Degron’s CEO on pipeline and strategy.